Azafaros will host a satellite symposium entitled "The value of conducting an 18-month placebo-controlled study in Rare Diseases: GM1, GM2 and NPC; the NAVIGATE experience" on February 3 at 17:45 PT, ...
Rutherford, NJ, May 02, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of ...
"Assessing Safety and Clinical Outcomes of Rinvecalinase Alfa (DM199) in Acute Ischemic Stroke Patients Pre-treated with Intravenous Thrombolytics Only" Expand The poster is P-704. On Thursday May 22, ...
PharmaJet needle-free technology can improve DNA vaccine delivery 1 and has been successfully adopted into multiple cancer vaccine development programs. Partner study data shows how PharmaJet ...
CORAL GABLES, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel ...
One researcher turned her scientific findings into character dialogue to simplify complex concepts. After seeing how ...
Three students pursuing degrees in biology won poster presentation awards at the Georgia Academy of Science conference hosted by Kennesaw State University. Maria Sanchez Acosta earned the Best Poster ...
Five presentations will showcase nizubaglustat's therapeutic potential in Lysosomal Storage Disorders. Nizubaglustat is currently being tested in two global Phase 3 studies for Niemann-Pick ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback